Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Zhu, Qiqi ^a   Feng, Chen ^a   Liao, Weiwei ^a   Zhang, Yan ^a   Tang, Suoqin ^a  

^a Hainan Branch of Chinese PLA General Hospital   (China)

Author keywords

Folate nanoliposomes; Metastatic neuroblastoma; MYCN; siRNA

Indexed keywords

FOLATE NANOLIPOSOME; LIPOSOME; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; V MYC MYELOCYTOMATOSIS VIRAL RELATED ONCOGENE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL;

EID: 84879454970     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-65     Document Type: Article

References (31)

1. Schor NF. Neuroblastoma as a neurobiological disease. J Neurooncol 1999, 41:159-166. 10.1023/A:1006171406740, 10222436.
2. Hogarty MD, Maris JM. PI3King On MYCN to improve neuroblastoma therapeutics. Cancer Cell 2012, 21:145-147. 10.1016/j.ccr.2012.01.018, 22340587.
3. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003, 4:472-480. 10.1016/S1470-2045(03)01166-5, 12901961.
4. Suenaga Y, Kaneko Y, Matsumoto D, Hossain MS, Ozaki T, Nakagawara A. Positive auto-regulation of MYCN in human neuroblastoma. Biochem Biophys Res Commun 2009, 390:21-26. 10.1016/j.bbrc.2009.09.044, 19766596.
5. Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 1999, 18:2916. 10.1038/sj.onc.1202748, 10378688.
6. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007, 59:75-86. 10.1016/j.addr.2007.03.005, 1978219, 17449137.
7. Jiang R, Xue S, Jin Z. Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo. Biochem Biophys Res Commun 2011, 410:364-370. 10.1016/j.bbrc.2011.06.020, 21683062.
8. Lovén J, Zinin N, Wahlström T, Müller I, Brodin P, Fredlund E, Ribacke U, Pivarcsi A, Påhlman S, Henriksson M. MYCN-regulated microRNAs repress estrogen receptor-α (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci 2010, 107:1553-1558. 10.1073/pnas.0913517107, 2824410, 20080637.
9. Heo I, Kim VN. Regulating the regulators: posttranslational modifications of RNA silencing factors. Cell 2009, 139:28-31. 10.1016/j.cell.2009.09.013, 19804751.
10. Fire A, Xu SQ, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811. 10.1038/35888, 9486653.
11. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007, 170:793. 10.2353/ajpath.2007.060929, 1864878, 17322365.
12. Daldrup-Link HE, Hawkins RA, Meier R, Goldsby RE, Artemov D. Receptor imaging of pediatric tumors: clinical practice and new developments. Pediatr Radiol 2008, 38:1154-1161. 10.1007/s00247-008-0878-x, 18483730.
13. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 1994, 269:3198-3204.
14. Rui Y, Wang S, Philip S, Thompson DH. Diplasmenylcholine-folate liposomes: an efficient vehicle for intracellular drug delivery. J Am Chem Soc 1998, 120:11213-11218.
15. Gabizon A, Horowitz AT, Goren D, Tzemach D, Mandelbaum-Shavit F, Qazen MM, Zalipsky S. Targeting folate receptor with folate linked to extremities of poly (ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 1999, 10:289-298. 10.1021/bc9801124, 10077479.
16. Tyagi N, Ghosh PC. Folate receptor mediated targeted delivery of ricin entrapped into sterically stabilized liposomes to human epidermoid carcinoma (KB) cells: Effect of monensin intercalated into folate-tagged liposomes. Eur J Pharm Sci 2011, 43:343-353. 10.1016/j.ejps.2011.05.010, 21621613.
17. Leamon CP, Weigl D, Hendren RW. Folate copolymer-mediated transfection of cultured cells. Bioconjug Chem 1999, 10:947-957. 10.1021/bc990066n, 10563763.
18. Reddy JA, Dean D, Kennedy MD, Low PS. Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. J Pharm Sci 1999, 88:1112-1118. 10.1021/js990169e, 10564057.
19. Reddy JA, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J Control Release 2000, 64:27-37. 10.1016/S0168-3659(99)00135-2, 10640643.
20. Reddy JA, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J Control Release 2000, 64:27-37. 10.1016/S0168-3659(99)00135-2, 10640643.
21. Sohara Y, Shimada H, Scadeng M, Pollack H, Yamada S, Ye W, Reynolds CP, DeClerck YA. Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Res 2003, 63:3026-3031.
22. Zhao H, Cai W, Li S, Da Z, Sun H, Ma L, Lin Y, Zhi D. Establishment and characterization of xenograft models of human neuroblastoma bone metastasis. Childs Nerv Syst 2012, 28:2047-2054. 10.1007/s00381-012-1909-3, 22983667.
23. Galderisi U, Di Bernardo G, Cipollaro M, Peluso G, Cascino A, Cotrufo R, Melone MAB. Differentiation and apoptosis of neuroblastoma cells: role of N-myc gene product. J Cell Biochem 1999, 73:97-105. 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M, 10088728.
24. Phoenix TN, Gilbertson RJ. There's a time and a place for MYCN. Cancer Cell 2012, 21:593-595. 10.1016/j.ccr.2012.05.001, 22624707.
25. Huang R, Cheung NKV, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J 2011, 25:4138-4149. 10.1096/fj.11-185033, 3236625, 21856782.
26. Corvi R, Savelyeva L, Breit S, Wenzel A, Handgretinger R, Barak J, Oren M, Amler L, Schwab M. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 1995, 10:1081.
27. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun 2006, 351:192-197. 10.1016/j.bbrc.2006.10.020, 2708968, 17055458.
28. Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, Fukuzawa M. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol 2007, 30:1189-1196.
29. Woo CW, Tan F, Cassano H, Lee JH, Lee KC, Thiele CJ. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. Pediatr Blood Cancer 2008, 50:208-212. 10.1002/pbc.21195, 17420990.
30. Bell E, Premkumar R, Carr J, Lu X, Lovat PE, Kees UR, Lunec J, Tweddle DA. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G. Cell Cycle 2006, 5:2639-2647. 10.4161/cc.5.22.3443, 17172827.
31. Biewenga JE, Destrée OHJ, Schrama LH. Plasmid-mediated gene transfer in neurons using the biolistics technique. J Neurosci Methods 1997, 71:67-75. 10.1016/S0165-0270(96)00127-6, 9125376.